Livestock production, particularly enteric methane production, contributes to greenhouse gas emissions globally. Various mitigation strategies developed to reduce enteric emissions have limited ...success. Although in vitro studies have shown a considerable reduction in methane emissions using Asparagopsis spp., no studies have been conducted to investigate the effect of any species of Asparagopsis in dairy cattle. Our objective was to evaluate quantitatively the response of cows consuming Asparagopsis armata on methane production (g/kg), yield (g/kg feed intake) and intensity (g/kg milk yield). Twelve post-peak lactating Holstein cows were randomly assigned to three treatments (control, 0.5% and 1% inclusion levels of A. armata on organic matter basis) in a 3 × 3 Latin square design with three 21-day periods. Enteric methane emissions were measured using the GreenFeed system. Methane production by cows decreased significantly by 26.4% at the low (0.5%) level of A. armata inclusion and 67.2% at the high (1%) level of inclusion. Feed intake was reduced by 10.8 and 38.0%, in cows fed the low and high level of macroalgae inclusion, respectively. Methane yield decreased significantly by 20.3 and 42.7% in cows fed diet including 0.5% and 1% A. armata inclusion levels, respectively (P = <0.0001). Methane intensity significantly decreased by 26.8% from cows fed at 0.5% level and 60% at the 1.0% A. armata inclusion level. Bromoform concentrations in milk were not significantly different between treatments. Our in vivo results showed that A. armata has potential to be used as a feed additive to reduce enteric methane emissions.
Display omitted
•Methane production by cows reduced up to 67% due to seaweed inclusion in diet.•Methane emissions reduced by up to 43% when normalized by how much cows consumed.•Adjusted for milk production methane emissions reduced by up to 60%.•Hydrogen and carbon dioxide emissions increased as methane emission decreased.
Gangrenous cholecystitis is an advanced form of acute cholecystitis associated with increased morbidity and mortality. We sought to determine the incidence of gangrenous cholecystitis in an urban VA ...hospital patient population and identify any distinguishing characteristics that may aid in its preoperative diagnosis. We retrospectively reviewed all urgent admissions that underwent cholecystectomy (n = 65) over the past 7 years at the Allen Park VAMC. Using histologic criteria, 17 (26%) of these patients had gangrenous cholecystitis. As a group compared to patients with nongangrenous cholecystitis, patients with gangrenous cholecystitis were statistically older (64 vs 54) and had an elevated WBC (15.4 vs 11.5) and increased serum glucose levels (203 vs 141). Preoperative imaging studies (ultrasound and cholescintigraphy) correctly identified only 31% of the gangrenous cholecystitis patients. We conclude that in an urban VA hospital patient population, the diagnosis of gangrenous cholecystitis cannot be accurately made or ruled out among urgent admissions with acute biliary disease. Considering the high incidence (26%) and difficulty confirming the diagnosis of gangrenous cholecystitis in this setting, we recommend early surgical intervention for this and similar patient populations.